Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Eurofarma Laboratorios S.A.
UNICANCER
Inovio Pharmaceuticals
Inovio Pharmaceuticals
Oncolytics Biotech
Gustave Roussy, Cancer Campus, Grand Paris
Vical